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Adventure travel is becoming more popular, increasing
the likelihood of contact with unusual pathogens. We inves-
tigated an outbreak of leptospirosis in “Eco-Challenge” mul-
tisport race athletes to determine illness etiology and imple-
ment public health measures. Of 304 athletes, we contact-
ed 189 (62%) from the United States and 26 other coun-
tries. Eighty (42%) athletes met our case definition. Twenty-
nine (36%) case-patients were hospitalized; none died.
Logistic regression showed swimming in the Segama River
(relative risk [RR]=2.0; 95% confidence interval [CI]=1.3 to
3.1) to be an independent risk factor. Twenty-six (68%) of
38 case-patients tested positive for leptospiral antibodies.
Taking doxycycline before or during the race was protective
(RR=0.4, 95% CI=0.2 to 1.2) for the 20 athletes who report-
ed using it. Increased adventure travel may lead to more
frequent exposure to leptospires, and preexposure chemo-
prophylaxis for leptospirosis (200 mg oral doxycycline/
week) may decrease illness risk. Efforts are needed to
inform adventure travel participants of unique infections
such as leptospirosis.
E
ach year, 60 million Americans travel abroad.
Increasingly, these persons are traveling to more
remote and exotic destinations. Adventure travel is now
the largest growing segment of the leisure travel industry,
with a growth rate of 10% per year since 1985 (Adventure
Travel Society, pers. comm.). This travel has led to an
increasing risk for contact with pathogens uncommon in
industrialized countries, especially for participants in
adventure sports and extreme travel. Both of these pursuits
may predispose persons to infection with unusual organ-
isms through exposures to lakes, rivers, caves, and
canyons, as well as insect vectors. These illnesses may be
unfamiliar to practitioners in the travelers’home countries,
and symptoms may go unrecognized. Leptospirosis, a bac-
terial zoonotic infection, is more frequently found in
developing countries, and its protean early symptoms may
be difficult to diagnose clinically. Prevention of leptospiro-
sis in humans has previously relied on mechanical barriers
and avoidance (1), but limited published data suggest that
preexposure chemoprophylaxis may be beneficial to some
groups (2–4).
From September 7 to September 11, 2000, the Idaho
Department of Health, the Los Angeles County
Department of Health Services, and the GeoSentinel
Network (an international surveillance network of travel
clinics) notified the Centers for Disease Control and
Prevention (CDC) of at least 20 cases of febrile illness.
The illness was characterized by the acute onset of high
fever, chills, headache, and myalgias; major laboratory test
abnormalities and important pulmonary or central nervous
system involvement were absent. All ill persons had partic-
ipated in the Eco-Challenge-Sabah 2000 multisport
endurance race, held in Malaysian Borneo August
21–September 1, 2000. Three hundred four athletes from
26 countries and 29 U.S. states competed in the 10-day
endurance event. Segments of the event included jungle
trekking, prolonged swimming and kayaking (both in fresh
and ocean water), spelunking (caving), climbing, and
mountain biking. Symptoms and exposure history, as well
as initial laboratory testing, suggested that the illness was
leptospirosis. We undertook an investigation to determine
the etiology of the illness in the athletes and to make pub-
lic health recommendations. We report on the results of
this investigation and discuss recommendations for pre-
venting leptospirosis in adventure travelers.
Methods
Epidemiologic Investigation
Upon identification of the first ill athletes, a complete
list of U.S. and international participants in the Eco-
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October 29–November 2, 2000.Challenge event, including their telephone numbers and
email addresses, was obtained from the race organizers. In
addition, race organizers and some athletes were inter-
viewed to determine details of the race activities, geogra-
phy of the course, and possible exposures. Athletes in the
United States were contacted by telephone, either by CDC
or by representatives of the athletes’ state or local health
departments, between September 7 and October 30, 2000.
International athletes were contacted by representatives
from their local ministries of health after notification by
local GeoSentinel sites or the World Health Organization. 
A standardized telephone questionnaire was adminis-
tered, directed at determining demographics, symptoms,
duration of illness, previous antibiotic use, and various
exposures encountered during the event. A clinical case of
illness was defined as onset of self-reported fever between
August 21 and September 30, 2000, in an Eco-Challenge
athlete, along with two or more of the following symp-
toms: chills, myalgias, headache, diarrhea, or conjunctivi-
tis. We compared clinical case-patients with controls from
the cohort of athletes to identify risk factors for illness.
Laboratory Investigations
Thirty-eight serum samples were obtained from a con-
venience sample of the cohort (who met the clinical case
definition) for laboratory testing for various pathogens. All
submitted samples were tested for Leptospira-specific
immunoglobulin (Ig) M antibodies by dot-enzyme-linked
immunosorbent assay (ELISA) dipstick (Dip-S-Ticks
immunoassay, Integrated Diagnostics, Baltimore, MD) or
by microplate IgM-ELISA (PanBio Ltd., Brisbane,
Australia), according to the manufacturer’s instructions.
Laboratory evidence for leptospirosis was defined as a
positive result for Leptospira-specific IgM antibodies. 
All 38 samples were subsequently tested by microscop-
ic agglutination test (MAT) by using a standard method
(5), with 23 live antigen suspensions representing 17
serogroups. Atiter of >200 against any of the antigens was
considered positive evidence for a probable case of lep-
tospirosis.
Given the broad differential diagnosis for febrile illness
in the tropics, 18 submitted samples were also tested for
alternative organisms. Samples with antibody responses to
Orientia tsutsugamushi,  Rickettsia prowazekii, and R.
typhi were assayed by using a variation of the standard
microimmunofluorescence test for rickettsiae (6). Testing
for flaviviruses (dengue, Japanese encephalitis, Powassan/
tick-borne encephalitis), alphaviruses (Chikungunya),
bunyaviruses (Snowshoe Hare virus), and hantaviruses
(Sin Nombre) was performed with the standard IgM
ELISA assay (7).
Statistical Analysis
Results of the telephone survey were entered into
EpiInfo v. 6.04b (CDC, Atlanta, GA); the dataset was then
imported into SAS v. 6.12 and v. 8.2 (SAS Institute Inc.,
Cary, NC) for subsequent analysis. Because laboratory
testing was only available from a subset of the cohort, ath-
letes were categorized on the basis of the clinical case def-
inition. All variables were examined using PROC GEN-
MOD (SAS). Those factors significant by univariate
analysis, as well as known risk factors, were examined in
a multivariable logistic regression model. Colinearity and
interaction among variables were calculated by using stan-
dard statistical techniques.
Results
Epidemiologic Investigation
Of the 304 athletes competing in the Eco-Challenge
event, 189 (62%) were contacted, including 129 (92%) of
the 140 U.S.-based athletes. The median age of the con-
tacted cohort was 34 years (range 21–50 years); 94% were
white, and 74% were men. No significant differences were
found between ill athletes who met the case definition and
non-ill athletes by age, race, or gender. The most common
symptoms athletes reported included fever, chills, muscle
aches, headache, and diarrhea (Table 1). Conjunctival suf-
fusion, a hallmark finding in persons infected with lep-
tospires, was reported by 40 (21%) athletes. Joint aches
and calf/leg pain were also frequently reported. The status
of athletes with respect to residence in an area endemic for
leptospirosis was unknown.
Of the 189 athletes contacted, 80 (42%) met the clinical
case definition. The median interval between the start of
the race and onset of fever was 15 days (range 1–24 days),
with a peak onset of fever on September 4, 2000 (Figure);
no cases were detected after September 13. The median
duration of illness was 7 days (range 1–17 days); 29 (36%)
of the athletes who met the clinical case definition were
hospitalized. No deaths were reported. Jaundice, pul-
monary hemorrhage, meningoencephalitis, or other severe
manifestations of leptospirosis were not reported. 
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Table 1. Self-reported clinical symptoms in Eco-Challenge 
athletes 
Symptom  % (n=189) 
Chills  50 
Muscle aches  50 
Fever  49 
Headache  47 
Diarrhea  33 
Joint aches  30 
Calf/leg pain  30 
Red eyes  22 
 On univariate analysis, statistically significant risk fac-
tors for illness included kayaking, swimming in the
Segama River, swallowing water from the Segama River,
and spelunking (Table 2). By multivariate stepwise logis-
tic regression, only swimming in the Segama River was
independently associated with illness. Adjusting for the
other variables did not alter the relative risk. The attribut-
able risk of river swimming was 36%.
Seventy-six teams, consisting of 4 members per team,
competed in Eco-Challenge; at least one member of 62
(82%) of the teams was administered the questionnaire. Of
the 51 teams with at least 2 members interviewed, illness
and team membership were not significantly associated
(data not shown).
Of the 189 athletes contacted, 20 (11%) reported taking
doxycycline for prophylaxis of either malaria or lep-
tospirosis. Seventeen of these athletes reported taking a
daily dose of doxycycline (100 mg by mouth) throughout
the duration of the race; the other three took daily doxycy-
cline, 100 mg by mouth, sporadically throughout the race.
Illness developed in 4 (20%) of the 20 athletes who report-
ed taking doxycycline. When the attack rate of those tak-
ing doxycycline was compared with the attack rate among
those not reporting doxycycline prophylaxis, and adjusted
for river swimming, doxycycline usage was protective,
although not significantly (relative risk [RR]=0.4, 95%
CI=0.1 to 1.1, p=0.1). The preventive efficacy attributable
to any doxycycline usage during the race was 55% (95%
CI=–0.05% to 95%).
Laboratory Investigation
Clinical symptoms of the athletes and the history of
extensive water exposure led to the early consideration of
leptospirosis as a diagnosis. In the first few days of the
investigation, serum specimens obtained from two of the
hospitalized athletes in California were tested at CDC for
anti-leptospiral IgM by dot-ELISA dipstick rapid assay;
one athlete had a positive test result on a serum specimen
obtained 4 days after onset of fever. The second athlete had
a negative test result for anti-leptospiral IgM on a serum
specimen obtained 4 days after onset of fever but a posi-
tive test result on a serum sample obtained 8 days after
fever onset. Based on these early results, further diagnos-
tic testing was directed toward leptospirosis.
Of the 80 athletes who met the case definition for ill-
ness, serum was collected from 38 (48%). The median
duration between onset of fever and the drawing of serum
from athletes was 10 days (range 3–34). Of these 38 sam-
ples, 26 (68%) tested positive by the dot-ELISA dipstick,
the IgM ELISA, or both. No differences in symptoms were
found between antibody-positive and antibody-negative
patients. Nine additional serum samples were obtained
from ill athletes who did not meet the clinical case defini-
tion; none of these samples tested positive by rapid assay.
Of the 26 samples testing positive by one or both rapid
assays, 20 (77%) were subsequently determined to be pos-
itive for anti-leptospiral antibodies by MAT. The serogroup
associated with the strongest MAT immunoreactivity was
Australis.
One culture-confirmed isolate was obtained from an
athlete in California. Based on its rrs and  secY gene
sequences, this isolate was determined to be most closely
related to Leptospira weilii, a species found exclusively in
Southeast Asia. Serologic analysis showed that the isolate
was most likely a new serovar of the Hebdomadis group
(8). 
Eighteen samples that tested negative for leptospiral
antibodies by rapid assay and MAT also tested negative for
dengue, typhoid, and scrub typhus antibodies, illnesses that
are clinically similar to leptospirosis. These samples includ-
ed 12 from athletes who met the case definition and 6 from
athletes who did not meet the definition. These 18 samples
also tested negative for antibodies to Chikungunya,
Powassan/tick-borne encephalitis, Sin Nombre virus,
Japanese encephalitis, and Snowshoe Hare virus.
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Figure. Date of fever onset for suspected and confirmed cases of
leptospirosis in Eco-Challenge-Sabah 2000 athletes, Malaysian
Borneo, August 21–September 14, 2000.
Table 2. Risk factors for developing illness, univariate analysis
a 
Exposure  % Ill (n=80)  % Not ill (n=109)  RR  95% CI  p value 
Swimming in Segama River  57  28  2.0  1.3 to 3.1  0.002 
Swallowing river water  45  21  1.8  1.2 to 2.9  0.008 
Kayaking  95  78  3.3  1.2 to 9.0  0.02 
Spelunking  87  68  2.2  1.1 to 4.2  0.02 
aRR, relative risk; CI, confidence interval. Discussion
This outbreak was the first recognized international
leptospirosis outbreak associated with the increasingly
popular activity of adventure travel. Data from this out-
break investigation suggest that doxycycline may be effec-
tive as prophylaxis for leptospirosis in persons with identi-
fiable, short-term exposure to high-risk activities and envi-
ronments. Preexposure chemoprophylaxis could be
increasingly important as more people engage in adventure
travel and eco-tourism. In addition, physicians treating
returning travelers should consider diseases such as lep-
tospirosis in patients with a history of water exposures.
Newer, rapid diagnostic assays may assist physicians in
earlier and more accurate diagnosis and, therefore, earlier
treatment. 
Leptospirosis is a zoonotic disease of worldwide distri-
bution that causes an acute febrile illness; the incubation
period is usually 5–14 days but ranges from 2 to 30 days
(9). The disease is associated with exposure to water or soil
that has been contaminated by a variety of wild and
domestic animals, which serve as reservoirs for leptospires
and transmit infection by shedding the organisms in their
urine (1). The illness is protean. It may be characterized by
abrupt onset of fever, chills, myalgias, and headache, and
may also include conjunctival suffusion, abdominal pain,
vomiting, diarrhea, and skin rashes. Severe leptospirosis
may include aseptic meningitis, jaundice, renal failure and
hemorrhage; the more severe syndrome characterized by
fever, meningismus, and renal and hepatic failure is
referred to as Weil’s disease. Mild infections can be treat-
ed with oral tetracyclines; more severe infections general-
ly require intravenous penicillin (9).
Among the Eco-Challenge athletes, symptoms and
exposure history suggested a diagnosis of leptospirosis;
this diagnosis was supported early in the investigation by
laboratory testing. Our investigation showed a high attack
rate in this cohort of athletes (nearly 50% in surveyed ath-
letes). Illness was also severe, with a hospitalization rate of
36% for young, otherwise exceptionally healthy endurance
athletes. On September 15, 2000, on the basis of this high
attack rate and high proportion of hospitalizations, CDC
recommended that all ill athletes be treated with empiric
doxycycline and that asymptomatic athletes discuss the
possible merits of a single dose of doxycycline with their
physicians (10). In addition, asymptomatic athletes were
advised to seek medical attention if signs and symptoms
consistent with leptospirosis developed. 
Although infection or coinfection with other pathogens
in ill athletes remains a possibility, testing for antibodies to
alternative pathogens commonly causing febrile disease in
the tropics was negative in the serum samples tested; most
ill athletes were likely infected with leptospires. The
known epidemiology of leptospirosis and the epidemiolog-
ic data gathered from this investigation suggested a point
source for the outbreak associated with exposure to water
from the Segama River. The attributable risk of swimming
in the river was 36%; those athletes whose illness could
not be accounted for by swimming in the river were likely
exposed to contaminated water or soil during some other
race activity, such as kayaking, trekking, or contact with
mud along the river banks. While our study did not find a
significant association between swallowing river water
and infection, a gastrointestinal route of infection after
swallowing contaminated water has also been suggested
(11).
Although previously reported in Malaysian Borneo,
leptospirosis was not recognized as a cause of a substantial
level of illness in Borneo at the time of Eco-Challenge.
The known epidemiology and pathophysiology of lep-
tospires suggest that the high attack rate among the athletes
was multifactorial. Contact with water from the Segama
River was preceded by prolonged treks through jungle
vegetation, and all surveyed athletes reported cuts and
abrasions (data not shown) that may have predisposed
them to a larger inoculum of organisms (12). Another pos-
sible factor in the high attack rate may have been rainfall
before the race. During Eco-Challenge, rainfall throughout
much of the race was heavy, and in the 3 months preced-
ing the event, regional monthly rainfall totals were approx-
imately 250 mm greater than the average for the previous
3 years (National Oceanic and Atmospheric
Administration, pers. comm.). Flooding, which has been
associated with previous leptospirosis outbreaks, elevates
the water table, saturating the soil with leptospires, pre-
venting evaporation of contaminated animal urine, and
potentially promoting the survival of leptospires in surface
waters (13–16). 
Leptospirosis is a relatively common zoonotic disease
in the tropics (9); however, it is frequently underdiagnosed
because of the nonspecific symptoms associated with
infection and the difficulty confirming a diagnosis. MAT is
considered the standard diagnostic criterion, but it is tech-
nically difficult, not widely available, and involves the use
of live leptospires, which presents a hazard to laboratory
personnel. A simple, accurate, rapid, and widely available
assay for detecting leptospires is needed. In this study, ini-
tial screening for leptospires was performed with the Dip-
S-Ticks immunoassay, an enzyme-linked dot immunoas-
say for detecting IgM antibodies; recent evaluations indi-
cate an overall case sensitivity of 98% and specificity of
91% (17,18). The assay has benefits over previous meth-
ods of Leptospira serodiagnosis because of its ease of use
and accessibility, as well as the rapidity of diagnosis; the
Dip-S-Ticks assay also has greater sensitivity early in
infection than other assays. Three Eco-Challenge athletes
tested positive by Dip-S-Ticks but negative by IgM ELISA
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response remains difficult; this low early sensitivity may
partially explain the 50% seronegativity rate in surveyed
athletes, given the 10-day median duration between onset
of fever and drawing of serum. The inability to obtain
MAT confirmation in all specimens that tested positive by
rapid assay may similarly be explained by the relatively
short interval between onset of fever and the drawing of
serum. While MAT reactivity can be seen several days
after infection, peak titers are frequently obtained in 2 to 3
weeks; sometimes, however, antibodies do not appear until
3–4 weeks after infection (1). Alternatively, serovars
responsible for infection may not have been included in the
testing battery used for the serum. The athletes did engage
in activities that may have led to multiple exposure risks,
and infection with other organisms might have accounted
for a proportion of those who tested seronegative for lep-
tospires. We tested some samples for pathogens that also
cause acute febrile illness in the tropics; none was detect-
ed. However, infection with other organisms remains a
possibility. 
Due in part to the antigenic heterogeneity among the
many different serovars of leptospires, a universally effec-
tive leptospirosis vaccine for humans has not been devel-
oped; in addition, the duration of immunity with current
serovar-specific leptospiral vaccines appears to be short-
lived (19). Prevention strategies for leptospirosis have tra-
ditionally relied on protective barriers such as wearing rub-
ber boots and gloves and avoiding high-risk areas.
However, several studies of persons from areas endemic
for leptospirosis and of military recruits with no known
prior exposure to leptospires have shown that doxycycline
given before or shortly after exposure can reduce illness
and death caused by leptospirosis (2–4). In our study, ath-
letes who took doxycycline for malaria prophylaxis were
less likely to become ill; although this finding did not
reach statistical significance, we may not have had suffi-
cient data to detect significance. Persons who travel to
areas where leptospirosis is endemic or epidemic and who
participate in high-risk exposure activities involving pro-
longed water exposure may be at increased risk for lep-
tospirosis (11,14,20,21) and may benefit from chemopro-
phylaxis. Until additional efficacy data are available, per-
sons at high risk for leptospirosis should consider chemo-
prophylaxis with doxycycline, 200 mg by mouth per week,
beginning 1–2 days before exposure and continuing for the
duration of suspected exposure. The role of other antimi-
crobial agents is not clear. Further randomized, controlled
studies assessing the utility and efficacy of doxycycline
and other antimicrobial agents for the prophylaxis of lep-
tospirosis are needed.
More people are participating in exotic travel, adven-
ture sports, and eco-tourism, and as a result, the potential
for contact with pathogens less common in the temperate,
industrialized world, such as Leptospira, is likely to
increase. Outbreaks of leptospirosis have previously been
documented in athletes participating in such activities as
kayaking (14), swimming (20), and triathlons (11).
Recently, leptospirosis in endurance athletes has been the
subject of several reports (22–24). In addition, previous
outbreaks of infectious disease attributable to other unusu-
al pathogens have been documented in adventure travelers
(25,26). Since leptospires are a common cause of febrile
illness in the tropics, physicians should evaluate travelers
with febrile illness returning from these areas for this and
other emerging infections. 
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